In vitro studies suggest that activation of class I A phosphatidylinositol 3 (PI-3) kinase is necessary for normal erythroid cell development. However, when class I A PI-3 kinase-deficient mice were generated by a targeted deletion of the p85␣ regulatory subunit, fetal erythropoiesis was reportedly unaffected. Given the discrepancies between these studies, we performed a more detailed in vivo analy- 
Introduction
Erythropoiesis is a coordinated process regulated by specific signaling pathways. In vitro studies suggest that activation of class I A phosphatidylinositol 3 (PI-3) kinase following binding of erythropoietin (Epo) and kit-ligand (KitL) to their receptors is required for the proliferation, survival, and differentiation of erythroid progenitors. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, the physiologic role of class I A PI-3 kinase in regulating fetal and adult erythropoiesis is not known. A class I A PI-3 kinase knock-out mouse was generated by a targeted deletion of the p85␣ regulatory subunit of this kinase. 11, 12 Although p85␣ Ϫ/Ϫ mice die shortly after birth secondary to hepatic necrosis and chylous ascites, 12 we used p85␣ Ϫ/Ϫ embryos to investigate the effect of p85␣ deficiency on fetal liver erythropoiesis in vivo.
Study design
Mice and fetal hematopoietic cell isolation p85␣ ϩ/Ϫ mice (129/SV ϫ C57BL/6) were obtained from Dr Lewis Cantley at Harvard University (Boston, MA). Studies were conducted with a protocol approved by the Indiana University Animal Care and Use Committee. The p85␣ allele was genotyped by polymerase chain reaction (PCR) as previously described. 11, 12 p85␣ ϩ/Ϫ mice were mated to produce day-14.5 p85␣ Ϫ/Ϫ and p85␣ ϩ/ϩ embryos. Fetal liver cells were isolated as previously described. 13 Single cell suspensions were prepared by pushing the hepatic tissues through a 23-gauge needle.
Peripheral blood analysis and fetal liver erythropoiesis
Embryonic blood was obtained from day-14.5 fetal hearts for peripheral smears, and fetal liver touch preps were performed as previously described 14 and stained with Wright-Giemsa (Dade Behring, Newark, DE). Photomicrographs of peripheral smears and touch preps were taken with an Olympus DP11 microscope (Melville, NY).
Colony assays
Recombinant KitL and Epo were obtained from Peprotech (Rocky Hill, NJ) and Amgen (Thousand Oaks, CA), respectively. Erythroid burst-forming unit (BFU-E) and erythroid colony-forming unit (CFU-E) assays were performed exactly as previously described. 15 
c-kit ؉ cell isolation
Fetal liver cells were incubated with 1 g phycoerythrin (PE)-conjugated c-kit monoclonal antibody (Pharmingen, San Diego, CA) per 10 6 cells, placed on ice for 20 minutes, pelleted, washed, and resuspended in phosphate-buffered saline (PBS). C-kit ϩ cells were purified by immunomagnetic bead enrichment as previously described. 15 Apoptosis and proliferation assays c-kit ϩ fetal liver cells were stained with fluorescein isothiocyanate (FITC)-annexin V (Pharmingen) and propidium iodide (Sigma, St Louis, MO) exactly per manufacturer's protocol followed by flow cytometric analysis as previously described. 16 For thymidine incorporation assays, 10 000 c-kit ϩ fetal liver cells were plated in 96-well plates in 5% fetal calf serum (BioWhittaker, Walkersville, MD) with Epo and KitL or no growth factors.
Results and discussion
To determine the effect of p85␣ deficiency on fetal liver erythropoiesis, p85␣ ϩ/Ϫ mice were intercrossed, and day-14.5 embryos were harvested for analysis. Day-14.5 p85␣ Ϫ/Ϫ embryos were pale compared with wild-type controls ( Figure 1A ) and demonstrated a marked reduction in the percentage of mature erythrocytes in their peripheral blood smears ( Figure 1B) . Most of the circulating cells in the p85␣ Ϫ/Ϫ embryos were nucleated megaloblasts or megalocytes (79% Ϯ 5% versus 26% Ϯ 8% for wild-type controls, n ϭ 7, P Ͻ .05). In contrast, in wild-type peripheral blood, 80% to 90% of circulating cells were enucleated, mature red blood cells, or macrocytes, whereas the remaining cells were yolk sac-derived megaloblasts ( Figure 1B ). This pattern was also demonstrated in day-14.5 fetal liver touch preps. Although there was a continuum of erythropoiesis in wild-type fetal liver, a predominance of nucleated erythroid precursors was present in p85␣ Ϫ/Ϫ fetal livers ( Figure 1C ).
We next assayed for early (BFU-E) and late (CFU-E) erythroid progenitors in wild-type and p85␣ Ϫ/Ϫ fetal livers. A marked reduction in the total number of BFU-E and CFU-E progenitors was observed in p85␣ Ϫ/Ϫ fetal livers compared with wild-type controls ( Figure 1D ). The reduction in BFU-Es and CFU-Es in p85␣ Ϫ/Ϫ fetal livers could be secondary to p85␣ deficiency in hematopoietic progenitors or alternatively a defect in the p85␣ Ϫ/Ϫ microenvironment. To directly test the effect of p85␣ deficiency on erythroid colony formation independent of the effects of the microenvironment, we performed BFU-E and CFU-E assays with equal numbers of sorted wild-type and p85␣ Ϫ/Ϫ c-kit ϩ cells, which are enriched for hematopoietic progenitors. A marked reduction in the frequency of both BFU-Es and CFU-Es was observed in c-kit ϩ cells isolated from day-14.5 p85␣ Ϫ/Ϫ fetal livers compared with wild-type controls ( Figure 1E) . Interestingly, the reduction in CFU-E frequency observed in p85␣ Ϫ/Ϫ c-kit ϩ cells was significantly greater when cells were stimulated with both KitL and Epo in combination compared with Epo alone ( Figure 1E ). Collectively, these results argue that an intrinsic p85␣ Ϫ/Ϫ hematopoietic progenitor cell defect contributes in part to the reduction of erythroid progenitors in day-14.5 p85␣ Ϫ/Ϫ fetal livers in vivo and the lack of mature erythrocytes in the peripheral blood of these affected fetuses.
Because these data establish a previously unrecognized role for p85␣ in regulating fetal erythropoiesis in vivo, we next tested whether the p85␣ Ϫ/Ϫ erythroid phenotype could be linked to either a decrease in proliferation and/or survival of hematopoietic progenitors. Prior studies argue that activation of the PI-3 kinase/Akt pathway by either Epo or KitL promotes the survival of erythroid progenitors. 1, 6, 8, 17 To test this hypothesis in vivo, we compared the percentage of both freshly isolated c-kit ϩ cells (a marker for early erythroid progenitors) or ter119 ϩ cells (a marker for late erythroid progenitors) undergoing apoptosis harvested from wild-type and p85␣ Ϫ/Ϫ day-14.5 fetal livers. Cells were stained with annexin to identify apoptotic cells. No differences in apoptosis in either c-kit ϩ or ter119 ϩ cells isolated from the 2 experimental genotypes wereobserved (Figure 2A ). These data are consistent with 2 recent reports which show that p85␣ Ϫ/Ϫ mast cells do not have an increase in apoptosis in response to KitL compared with wild-type controls. 18, 19 We next tested whether p85␣ deficiency would alter the proliferation of c-kit ϩ progenitor cells in response to either KitL or c-kit ϩ cells were isolated by immunomagnetic bead enrichment and sorted as previously described. 15 More than 90% of the cells were c-kit ϩ after sorting as tested by fluorescence cytometry (data not shown). c-kit ϩ cells/mL (2000) were plated in methylcellulose medium containing KitL (10 ng/mL) and Epo (5 U/mL), and the numbers of CFU-Es and BFU-Es were quantified after 2 and 7 days of culture, respectively. In addition, 2000 c-kit ϩ cells/mL were plated in methylcellulose medium containing Epo (5 U/mL) alone, and the number of CFU-Es was counted after 2 days of culture. Results represent the mean number of colonies per 2000 c-kit ϩ cells Ϯ SEM of 3 independent experiments. *P Ͻ .05 by Student paired t test.
Epo alone or in combination. Remarkably, p85␣ Ϫ/Ϫ c-kit ϩ cells displayed a 40% to 50% reduction in proliferation in response to KitL alone or KitL in combination with Epo compared with wild-type cells ( Figure 2B ). Such a proliferative defect would account for the diminished number of erythroid progenitors measured in the day-14.5 p85␣ Ϫ/Ϫ embryos. This finding would explain why knock-in mice harboring a mutation in the p85␣ binding domain of the c-kit receptor are not anemic as adult animals, 20 whereas we note an erythropoietic defect in p85␣ Ϫ/Ϫ fetal livers. It is well known that rates of hematopoietic progenitor proliferation are approximately 2-fold higher in fetal liver compared with adult bone marrow under normal homeostatic conditions. 21 Thus, a defect in basal and stimulated progenitor proliferation would affect fetal liver more than adult hematopoiesis. Further, other hematopoietic growth factors or integrins may act in synergy with KitL to transmit signals via class I A PI-3 kinase to augment the proliferation of erythroid progenitors. This situation would result in a more anemic phenotype in p85␣ Ϫ/Ϫ animals compared with mice containing only a mutation in the p85␣ binding site of the c-kit receptor. Finally, p85␣ Ϫ/Ϫ c-kit ϩ cells stimulated with Epo alone demonstrated only a 10% reduction in proliferation compared with wild-type cells ( Figure 2B ). This finding is consistent with the observation that mutant mice harboring an Epo receptor, which lacks the p85␣ binding site, are viable with relatively normal adult erythropoiesis. 22 This observation is also consistent with our clonogenic data, which showed that p85␣ Ϫ/Ϫ c-kit ϩ cells had only a minor decrease in CFU-E formation in response to Epo alone ( Figure 1E) .
Thus, these studies clearly establish and clarify a role for p85␣ and class I A PI-3 kinase in regulating normal fetal erythropoiesis in vivo at least in part by promoting the proliferation of hematopoietic progenitors via signaling through the KitL/c-kit pathway. Our studies did not find a role for p85␣ in controlling the survival of c-kit ϩ cells in vivo. However, Akt activation in p85␣ Ϫ/Ϫ c-kit ϩ cells in response to either Epo or KitL was reduced by only 30% to 40% compared with wild-type controls (data not shown), which is consistent with previous studies using other primary p85␣ Ϫ/Ϫ cell lines stimulated with different growth factors. 11, 12, 18, 19, 23 The retention of a significant amount of Akt activity in our p85␣ Ϫ/Ϫ cells may explain the differences in our results and previous in vitro studies using pharmacologic inhibitors of PI-3 kinase. Future studies designed to further reduce class I A PI-3 kinase activity in vivo in genetically engineered animal models will clarify the role of this kinase in regulating both fetal and adult erythropoiesis. 
